# SLPI

## Overview
The SLPI gene encodes the secretory leukocyte peptidase inhibitor, a small protein belonging to the whey acidic protein (WAP) family, characterized by its protease inhibitory activity. This protein plays a crucial role in the immune system by inhibiting serine proteases such as neutrophil elastase and cathepsin G, thereby protecting tissues from excessive proteolytic damage and inflammation (Nugteren2021Secretory; Abe1991Expression). SLPI is predominantly expressed at mucosal surfaces, including the respiratory, gastrointestinal, and genitourinary tracts, where it contributes to both anti-inflammatory and antimicrobial defenses (Nugteren2021Secretory). Beyond its protease inhibition, SLPI exhibits broad-spectrum antimicrobial properties and modulates immune responses, making it a key player in maintaining mucosal immunity and homeostasis (Nugteren2021Secretory).

## Structure
The secretory leukocyte protease inhibitor (SLPI) is a protein composed of a single polypeptide chain with 107 amino acids, resulting in a molecular weight of approximately 11.7 kDa (Small2016The; Thompson1986Isolation). SLPI is organized into two homologous domains, each containing about 54 amino acids, and is characterized by a boomerang-like shape (Grütter1988The; Eisenberg1990Location). These domains are connected by four disulfide bridges, which contribute to the protein's stability and unique folding pattern (Thompson1986Isolation; Grütter1988The).

The secondary structure of SLPI includes a two-stranded beta-sheet with a hairpin turn, surrounded by an N-terminal segment connected through disulfide bridges, hydrogen bonds, and hydrophobic contacts (Grütter1988The). The protein's tertiary structure is stabilized by these disulfide bonds, forming a four-disulfide core, which is a characteristic feature of the whey acidic protein (WAP) family to which SLPI belongs (Small2016The; Baranger2011Secretory).

SLPI does not typically form quaternary structures, and its post-translational modifications may include glycosylation (Small2016The). The protein's structure allows it to inhibit a range of proteases, with specific binding sites located in the COOH-terminus, particularly effective against neutrophil elastase (Small2016The; Eisenberg1990Location).

## Function
The Secretory Leukocyte Protease Inhibitor (SLPI) gene encodes a protein that plays a multifaceted role in maintaining homeostasis in healthy human cells. SLPI is primarily known for its ability to inhibit serine proteases, such as neutrophil elastase and cathepsin G, which are involved in tissue degradation and inflammation (Nugteren2021Secretory; Abe1991Expression). This protein is expressed at mucosal surfaces, including the respiratory, gastrointestinal, and genitourinary tracts, where it contributes to anti-inflammatory and antimicrobial defense mechanisms (Nugteren2021Secretory).

SLPI exerts its anti-inflammatory effects by inhibiting nuclear factor-kappa B (NF-κB)-mediated inflammatory gene transcription, thereby reducing the production of pro-inflammatory cytokines and modulating immune cell recruitment and function (Nugteren2021Secretory). It also plays a role in wound healing by suppressing immune cell infiltration and preventing excessive tissue contraction, which can lead to scarring (Nugteren2021Secretory).

In addition to its protease inhibitory activity, SLPI has broad-spectrum antimicrobial properties, including antibacterial, antifungal, and antiviral activities, such as against HIV-1 (Nugteren2021Secretory). It is involved in maintaining mucosal immune tolerance by attenuating dendritic cell activation and supporting regulatory T cell responses (Nugteren2021Secretory).

## Clinical Significance
Alterations in the expression of the SLPI gene have been implicated in various diseases, particularly in cancer and inflammatory conditions. In cancer, SLPI expression is often upregulated in gynecological cancers such as ovarian, uterine, and cervical cancers, where it may promote malignancy through its protease inhibitory activity (DEVOOGDT2004Secretory). Conversely, SLPI is generally downregulated in breast cancer, where its lower expression is associated with worse prognosis and is negatively correlated with estrogen and progesterone receptor status (Xie2019The). In oral squamous cell carcinoma, reduced SLPI levels are linked to more advanced disease stages, suggesting its potential role as a biomarker for malignant transformation (Wang2018Secretory).

In inflammatory lung diseases, SLPI plays a protective role by modulating inflammation. Its expression is influenced by hormonal factors, such as estrogen, which can upregulate SLPI in conditions like cystic fibrosis, potentially affecting disease severity in females (McKiernan2011SLPI). In severe asthma, a dysregulated IFN-γ/SLPI axis is observed, with reduced SLPI expression correlating with increased airway hyperresponsiveness, highlighting its potential as a therapeutic target (Raundhal2015High).

## Interactions
SLPI (secretory leukocyte peptidase inhibitor) interacts with various proteins and nucleic acids, playing a significant role in immune response modulation and protease inhibition. It binds to scramblase 1, a membrane protein that interacts with CD4, interfering with HIV fusion with the T-cell plasma membrane. SLPI also binds to annexin II, a macrophage receptor, blocking viral entry and fusion with myeloid cells (Nugteren2021Secretory; Drannik2011War).

SLPI's antiprotease activity involves interactions with neutrophil serine proteases, such as neutrophil elastase, and it is a major inhibitor of these proteases in the cytoplasm of neutrophils (Nugteren2021Secretory). It can be inactivated by neutrophils through myeloperoxidase-catalyzed oxidation and is cleaved by MMP-9, chymase, and cathepsins B, L, and S, which reduces its ability to inhibit neutrophil elastase (Nugteren2021Secretory).

SLPI also interacts with nucleic acids, binding to bacterial mRNA and DNA, which inhibits translation and arrests bacterial growth (Nugteren2021Secretory). These interactions highlight SLPI's multifaceted role in immune defense and its potential therapeutic applications.


## References


[1. (Nugteren2021Secretory) Sandrine Nugteren and Janneke N. Samsom. Secretory leukocyte protease inhibitor (slpi) in mucosal tissues: protects against inflammation, but promotes cancer. Cytokine &amp; Growth Factor Reviews, 59:22–35, June 2021. URL: http://dx.doi.org/10.1016/j.cytogfr.2021.01.005, doi:10.1016/j.cytogfr.2021.01.005. This article has 43 citations.](https://doi.org/10.1016/j.cytogfr.2021.01.005)

[2. (Baranger2011Secretory) Kévin Baranger, Marie-Louise Zani, Valérie Labas, Sandrine Dallet-Choisy, and Thierry Moreau. Secretory leukocyte protease inhibitor (slpi) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate. PLoS ONE, 6(6):e20976, June 2011. URL: http://dx.doi.org/10.1371/journal.pone.0020976, doi:10.1371/journal.pone.0020976. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0020976)

[3. (DEVOOGDT2004Secretory) NICK DEVOOGDT, HILDE REVETS, GHOLAMREZA HASSANZADEH GHASSABEH, and PATRICK DE BAETSELIER. Secretory leukocyte protease inhibitor in cancer development. Annals of the New York Academy of Sciences, 1028(1):380–389, December 2004. URL: http://dx.doi.org/10.1196/annals.1322.044, doi:10.1196/annals.1322.044. This article has 44 citations and is from a peer-reviewed journal.](https://doi.org/10.1196/annals.1322.044)

[4. (Eisenberg1990Location) S P Eisenberg, K K Hale, P Heimdal, and R C Thompson. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. Journal of Biological Chemistry, 265(14):7976–7981, June 1990. URL: http://dx.doi.org/10.1016/s0021-9258(19)39026-x, doi:10.1016/s0021-9258(19)39026-x. This article has 131 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(19)39026-x)

[5. (McKiernan2011SLPI) Paul J. McKiernan, Noel G. McElvaney, and Catherine M. Greene. Slpi and inflammatory lung disease in females. Biochemical Society Transactions, 39(5):1421–1426, September 2011. URL: http://dx.doi.org/10.1042/bst0391421, doi:10.1042/bst0391421. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst0391421)

[6. (Thompson1986Isolation) R C Thompson and K Ohlsson. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proceedings of the National Academy of Sciences, 83(18):6692–6696, September 1986. URL: http://dx.doi.org/10.1073/pnas.83.18.6692, doi:10.1073/pnas.83.18.6692. This article has 346 citations.](https://doi.org/10.1073/pnas.83.18.6692)

[7. (Raundhal2015High) Mahesh Raundhal, Christina Morse, Anupriya Khare, Timothy B. Oriss, Jadranka Milosevic, John Trudeau, Rachael Huff, Joseph Pilewski, Fernando Holguin, Jay Kolls, Sally Wenzel, Prabir Ray, and Anuradha Ray. High ifn-γ and low slpi mark severe asthma in mice and humans. Journal of Clinical Investigation, 125(8):3037–3050, June 2015. URL: http://dx.doi.org/10.1172/jci80911, doi:10.1172/jci80911. This article has 303 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci80911)

[8. (Xie2019The) WenTing Xie, Han Zhang, ShanShan Qin, JiaJia Zhang, Xin Fan, YuZhen Yin, RuiPeng Liang, HuiDeng Long, WanWan Yi, Da Fu, Chao Ma, MingLi Lv, and Fei Yu. The expression and clinical significance of secretory leukocyte proteinase inhibitor (slpi) in mammary carcinoma using bioinformatics analysis. Gene, 720:144088, December 2019. URL: http://dx.doi.org/10.1016/j.gene.2019.144088, doi:10.1016/j.gene.2019.144088. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2019.144088)

[9. (Abe1991Expression) T Abe, N Kobayashi, K Yoshimura, B C Trapnell, H Kim, R C Hubbard, M T Brewer, R C Thompson, and R G Crystal. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. Journal of Clinical Investigation, 87(6):2207–2215, June 1991. URL: http://dx.doi.org/10.1172/jci115255, doi:10.1172/jci115255. This article has 107 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci115255)

[10. (Small2016The) Donna M. Small, Declan F. Doherty, Caoifa M. Dougan, Sinéad Weldon, and Clifford C. Taggart. The role of whey acidic protein four-disulfide-core proteins in respiratory health and disease. Biological Chemistry, 398(4):425–440, October 2016. URL: http://dx.doi.org/10.1515/hsz-2016-0262, doi:10.1515/hsz-2016-0262. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/hsz-2016-0262)

[11. (Wang2018Secretory) Xin Wang, Yu Jin, Yue-Xiu Li, and Ya Yang. Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma. Oncology Reports, February 2018. URL: http://dx.doi.org/10.3892/or.2018.6251, doi:10.3892/or.2018.6251. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2018.6251)

[12. (Drannik2011War) Anna G. Drannik, Bethany M. Henrick, and Kenneth L. Rosenthal. War and peace between wap and hiv: role of slpi, trappin-2, elafin and ps20 in susceptibility to hiv infection. Biochemical Society Transactions, 39(5):1427–1432, September 2011. URL: http://dx.doi.org/10.1042/bst0391427, doi:10.1042/bst0391427. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1042/bst0391427)

[13. (Grütter1988The) M. G. Grütter, G. Fendrich, R. Huber, and W. Bode. The 2.5 a x-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha-chymotrypsin. The EMBO Journal, 7(2):345–351, February 1988. URL: http://dx.doi.org/10.1002/j.1460-2075.1988.tb02819.x, doi:10.1002/j.1460-2075.1988.tb02819.x. This article has 180 citations.](https://doi.org/10.1002/j.1460-2075.1988.tb02819.x)